LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF7 | Tozasertib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 1530 | 5905 | 0.2591 | 0.0471 |
MCF7 | Seliciclib | 0.37 | uM | LJP5 | 72 | hr | 1389 | 5718 | 5905 | 0.9670 | 0.9662 |
MCF7 | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 1389 | 5969 | 5905 | 1.0110 | 1.0106 |
MCF7 | CGP60474 | 0.37 | uM | LJP5 | 72 | hr | 1389 | 465 | 5905 | 0.0787 | -0.4081 |
MCF7 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 1389 | 6297 | 5905 | 1.0662 | 1.0623 |
MCF7 | CP466722 | 0.12 | uM | LJP5 | 72 | hr | 1389 | 6357 | 5905 | 1.0767 | 1.0722 |
MCF7 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 1389 | 5956 | 5905 | 1.0082 | 1.0075 |
MCF7 | CP466722 | 1.11 | uM | LJP5 | 72 | hr | 1389 | 5956 | 5905 | 1.0090 | 1.0087 |
MCF7 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 1389 | 5916 | 5905 | 1.0023 | 1.0024 |
MCF7 | CP466722 | 10 | uM | LJP5 | 72 | hr | 1389 | 5776 | 5905 | 0.9766 | 0.9750 |
MCF7 | CP724714 | 0.04 | uM | LJP5 | 72 | hr | 1389 | 5239 | 5905 | 0.8877 | 0.8892 |
MCF7 | CP724714 | 0.12 | uM | LJP5 | 72 | hr | 1389 | 4654 | 5905 | 0.7877 | 0.7836 |
MCF7 | CP724714 | 0.37 | uM | LJP5 | 72 | hr | 1389 | 4622 | 5905 | 0.7829 | 0.7787 |
MCF7 | CP724714 | 1.11 | uM | LJP5 | 72 | hr | 1389 | 4672 | 5905 | 0.7922 | 0.7888 |
MCF7 | CP724714 | 3.33 | uM | LJP5 | 72 | hr | 1389 | 5059 | 5905 | 0.8573 | 0.8579 |
MCF7 | CP724714 | 10 | uM | LJP5 | 72 | hr | 1389 | 3532 | 5905 | 0.5978 | 0.5625 |
MCF7 | HG-5-113-01 | 10 | uM | LJP5 | 72 | hr | 1389 | 990 | 5905 | 0.1674 | -0.1512 |
MCF7 | Neratinib | 0.37 | uM | LJP5 | 72 | hr | 1389 | 3852 | 5905 | 0.6518 | 0.6287 |
MCF7 | Neratinib | 1.11 | uM | LJP5 | 72 | hr | 1389 | 3862 | 5905 | 0.6527 | 0.6278 |
MCF7 | Neratinib | 10 | uM | LJP5 | 72 | hr | 1389 | 2041 | 5905 | 0.3462 | 0.2026 |
MCF7 | Dasatinib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 3839 | 5905 | 0.6494 | 0.6252 |
MCF7 | Seliciclib | 10 | uM | LJP5 | 72 | hr | 1389 | 1278 | 5905 | 0.2160 | -0.0411 |
MCF7 | Dasatinib | 10 | uM | LJP5 | 72 | hr | 1389 | 1168 | 5905 | 0.1977 | -0.0803 |
MCF7 | Crizotinib | 0.12 | uM | LJP5 | 72 | hr | 1389 | 4580 | 5905 | 0.7740 | 0.7660 |
MCF7 | Crizotinib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 4267 | 5905 | 0.7211 | 0.7069 |